Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling
Abstract Triple-negative breast cancer (TNBC) exhibits the poorest outcomes among breast cancer subtypes due to the high heterogeneity and a lasting scarcity of effectual treatments. Targeted therapies based on molecular subtypes of TNBC are critical step toward tailoring treatments to improve clini...
Main Authors: | Heshu Liu, Rui Yan, Zeru Xiao, Xuying Huang, Jiannan Yao, Jian Liu, Guangyu An, Yang Ge |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-04-01
|
Series: | Breast Cancer Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13058-023-01642-3 |
Similar Items
-
DCLK1 Suppresses Tumor-Specific Cytotoxic T Lymphocyte Function Through Recruitment of MDSCs via the CXCL1-CXCR2 AxisSummary
by: Rui Yan, et al.
Published: (2023-01-01) -
DCLK1 autoinhibition and activation in tumorigenesis
by: Linna Cheng, et al.
Published: (2022-01-01) -
Oncogenic functions and clinical significances of DCLK1 isoforms in colorectal cancer: a systematic review and meta-analysis
by: Elham Kalantari, et al.
Published: (2022-06-01) -
Knockdown of DCLK1 Inhibits Proliferation, Migration and Invasion of Glioma Cells
by: YU Jie, et al.
Published: (2020-09-01) -
Macrophage DCLK1 promotes atherosclerosis via binding to IKKβ and inducing inflammatory responses
by: Zhuqi Huang, et al.
Published: (2023-03-01)